Pulmonary Function Testing (PFT) is a vital tool in the diagnosis, monitoring, and management of respiratory diseases. Despite its importance, the interpretation of PFT results can be challenging for healthcare professionals. This article aims to demystify PFT interpretation, outlining the essential components and their clinical implications.
The basic PFT parameters include Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), and the FEV1/FVC ratio. FVC reflects the maximum volume of air that can be forcibly exhaled, while FEV1 indicates the volume exhaled in the first second. The FEV1/FVC ratio is a critical indicator of obstructive and restrictive lung diseases.
In obstructive lung diseases, such as Chronic Obstructive Pulmonary Disease (COPD) and asthma, the FEV1/FVC ratio is typically reduced (<70%). Conversely, restrictive diseases like pulmonary fibrosis are characterized by a normal or increased FEV1/FVC ratio alongside a reduced FVC.
The severity of a respiratory condition is gauged using the percent predicted FEV1. A value of less than 80% indicates disease presence, with severity ranging from mild (>70%) to very severe (<30%).
DLCO measures the lung's ability to transfer gas from inhaled air to the red blood cells. It is particularly useful in diagnosing and monitoring conditions such as emphysema and pulmonary fibrosis.
Understanding PFT interpretation is crucial for healthcare professionals in the effective management of respiratory diseases. By familiarizing themselves with the basic parameters and their implications, clinicians can make more accurate diagnoses, monitor disease progression, and optimize patient care.
1.
FDA Declines to Approve Achieve Life Sciences' Smoking-cessation Drug
2.
Uncovered biology underlies a novel drug used to treat triple-negative breast cancer.
3.
Chemotherapy damage to non-cancer cells may be the cause of breast cancer recurrence.
4.
Never in a million years did I think I'd have to limit my chemotherapy.
5.
Treating Depression: Crucial for Recovery From Fibromyalgia
1.
HCC in Melanoma: Role of HCC Codes and Moderate Whole Body Hyperthermia
2.
Clinical Analysis of Prostate Cancer
3.
Sorafenib: Understanding the science behind a powerful cancer drug
4.
Early-Onset GI Cancers: Screening, AI Innovations & Research Advances 2025
5.
Comprehensive Breakthroughs in Oncology for Better Care
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Understanding the Evolution in Lung Cancer- An Initiative from Manipal Hospitals: Further Discussion
2.
Experts' Opinion on the Goal of Treatment of Patients with Relapsed Adult B-cell ALL
3.
A Continuation to Deep Dive Into EGFR Mutation Positive Non-Small Cell Lung Cancer
4.
EGFR Mutation Positive Non-Small Cell Lung Cancer- Case Discussion & Conclusion
5.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation